NewLimit

NewLimit is a biotechnology company focused on extending human healthspan by unlocking regenerative potential. It builds therapies and platform technologies aimed at restoring youthful function to tissues and organs by targeting core cellular and molecular drivers of aging. NewLimit advances programs through preclinical research and collaborations to translate regenerative biology into treatments for age‑related disease. The company emphasizes translational science with the goal of delivering durable, clinically meaningful rejuvenation across organ systems.